UCH-L1 Inhibitor

A potent, reversible, competitive, and active site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1) (K_i = 400 nM; IC₅₀ = 880 nM). Exhibits ~28-fold greater selectivity for UCH-L1 compared to UCH-L3 (Cat. No. 662090). Shown to increase proliferation of the UCH-L1-expressing tumor cell line, SH-SY5Y, at a concentration of 5 µM. Useful tool for studying the roles of UCH-L1 in cancer, Parkinson′s disease, and other neurological disorders. Cell-permeability is reported to vary from cell type to cell type.

An isatin O-acyl oxime compound that acts as a potent, reversible, competitive, and active site-directed inhibitor of UCH-L1 (K_i = 0.40 µM; IC₅₀ = 0.88 µM) with ~28-fold greater selectivity over UCH-L3 (Cat. No. 662090). Shown to increase proliferation of UCH-L1 expresssing tumor cell line SH-SY5Y at 5 µM. A useful tool for studying the roles of UCH-L1 in cancer, Parkinson’s disease, and other neurological disorders. Permeability may vary from cell type to cell type.

Cell permeable: no

Primary Target
UCH-L1

Product competes with ATP.

Reversible: yes

Packaged under inert gas

Toxicity: Carcinogenic / Teratogenic (D)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Liu, Y., et al. 2003. Chem. Biol.10, 837.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany